|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0020179,
umls-concept:C0025936,
umls-concept:C0026187,
umls-concept:C0026336,
umls-concept:C0026565,
umls-concept:C0185117,
umls-concept:C0205421,
umls-concept:C0291573,
umls-concept:C0534519,
umls-concept:C2911684
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2000-7-31
|
|
pubmed:abstractText |
Huntington disease is an autosomal dominant neurodegenerative disease with no effective treatment. Minocycline is a tetracycline derivative with proven safety. After ischemia, minocycline inhibits caspase-1 and inducible nitric oxide synthetase upregulation, and reduces infarction. As caspase-1 and nitric oxide seem to play a role in Huntington disease, we evaluated the therapeutic efficacy of minocycline in the R6/2 mouse model of Huntington disease. We report that minocycline delays disease progression, inhibits caspase-1 and caspase-3 mRNA upregulation, and decreases inducible nitric oxide synthetase activity. In addition, effective pharmacotherapy in R6/2 mice requires caspase-1 and caspase-3 inhibition. This is the first demonstration of caspase-1 and caspase-3 transcriptional regulation in a Huntington disease model.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Bacterial Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Casp3 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Caspase 1,
http://linkedlifedata.com/resource/pubmed/chemical/Caspase 3,
http://linkedlifedata.com/resource/pubmed/chemical/Caspases,
http://linkedlifedata.com/resource/pubmed/chemical/Minocycline,
http://linkedlifedata.com/resource/pubmed/chemical/Neuroprotective Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Nitric Oxide Synthase,
http://linkedlifedata.com/resource/pubmed/chemical/Nitric Oxide Synthase Type II,
http://linkedlifedata.com/resource/pubmed/chemical/Nos2 protein, mouse
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1078-8956
|
|
pubmed:author |
pubmed-author:BiasGG,
pubmed-author:ChenMM,
pubmed-author:FarrellL ALA,
pubmed-author:FerranteR JRJ,
pubmed-author:FinnK CKC,
pubmed-author:FriedlanderR MRM,
pubmed-author:HerschS MSM,
pubmed-author:HobbsWW,
pubmed-author:MADD,
pubmed-author:ObaM SMS,
pubmed-author:OngV YVY,
pubmed-author:VonsattelJ PJP,
pubmed-author:YUH IHI,
pubmed-author:ZinKK
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
797-801
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10888929-Animals,
pubmed-meshheading:10888929-Anti-Bacterial Agents,
pubmed-meshheading:10888929-Caspase 1,
pubmed-meshheading:10888929-Caspase 3,
pubmed-meshheading:10888929-Caspases,
pubmed-meshheading:10888929-Disease Models, Animal,
pubmed-meshheading:10888929-Disease Progression,
pubmed-meshheading:10888929-Enzyme Activation,
pubmed-meshheading:10888929-Evaluation Studies as Topic,
pubmed-meshheading:10888929-Gene Expression Regulation,
pubmed-meshheading:10888929-Huntington Disease,
pubmed-meshheading:10888929-Mice,
pubmed-meshheading:10888929-Mice, Transgenic,
pubmed-meshheading:10888929-Minocycline,
pubmed-meshheading:10888929-Neuroprotective Agents,
pubmed-meshheading:10888929-Nitric Oxide Synthase,
pubmed-meshheading:10888929-Nitric Oxide Synthase Type II,
pubmed-meshheading:10888929-Transcription, Genetic
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.
|
|
pubmed:affiliation |
Neuroapoptosis Laboratory, Neurosurgical Service, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't
|
